Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653856 · ClinicalTrials.gov registry record · Phase 2
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
A Phase 2 study of Metastasis From Malignant Tumor of Prostate (Disorder), sponsored by Curium US.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 9
- Study locations
NCT05653856 is a Phase 2 study of Metastasis From Malignant Tumor of Prostate (Disorder) that has completed, run by Curium US. The registered enrollment target is 26 participants. The trial reports 9 study locations across 6 states.
The verdict
NCT05653856, a Phase 2 study of Metastasis From Malignant Tumor of Prostate (Disorder), has completed, sponsored by Curium US.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
Conditions Studied
Interventions
- DRUG 64Cu-PSMA I&T
Study Locations (9)
Missouri
- Saint Louis University - St Louis
- John J. Cochran Veterans Hospital - St Louis
- Washington University - St Louis
Nebraska
- Nebraska Cancer Specialists - Omaha
- XCancer Omaha/Urology Cancer Center - Omaha
Connecticut
- Yale University - New Haven
Illinois
- Edward Hines, Jr. VA Hospital - Hines
Maryland
- Johns Hopkins University - Baltimore
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-12-05 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05653856
The ClinicalTrials.gov registry entry for NCT05653856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curium US, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastasis From Malignant Tumor of Prostate (Disorder) appearing as the primary indexed condition, and to 1 intervention - of which 64Cu-PSMA I&T is the first listed.
NCT05653856 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Missouri, Nebraska, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05653856 about?
NCT05653856 is a clinical study titled "Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer". This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
What is the current status of trial NCT05653856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2022-12-05. Estimated completion is 2023-05-17.
What conditions does trial NCT05653856 study?
This clinical trial studies the following conditions: Metastasis From Malignant Tumor of Prostate (Disorder).
What interventions are being tested in trial NCT05653856?
The interventions under investigation include: 64Cu-PSMA I&T (DRUG).
Who is sponsoring clinical trial NCT05653856?
This trial is sponsored by Curium US, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653856 being conducted?
This trial has 9 study locations across Connecticut, Illinois, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.